ClinicalTrials.gg
CompletedNCT02411695Updated Apr 28, 2026

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

A Phase 1 interventional study of Brexpiprazole (OPC-34712) in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 10 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
21st of 28
43 · median 155
Started
2015
with 1 other
Phase 1
8 of 28
1 open now
Registered
20th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 21st largest by enrollment, is one of 2 that started in 2015, is one of 8 in phase 1, and was the 20th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral brexpipirazole in adolescent subjects with schizophrenia or Other Related Psychiatric Disorders.

Read the detailed description

Schizophrenia is a severely delibitating mental illness that affects approximately 1% of the world population. The onset of schizophrenia symptoms typically peaks in late adolescence and early adulthood. In a minority of cases, the initial episode may occur during childhood or early adolescence. Patients who experience this "early-onset schizophrenia" exhibit symptoms that are more severe and follow a more chronic course; adolescents with schizophrenia may never achieve full remission of the initial episode. The prognosis for early-onset schizophrenia tends to be poor, and cognitive impairment is greater compared with individuals whose onset of schizophrenia occurs later in life. Several antipsychotics have been investigated for the treatment of adolescent schizophrenia, however, there is a particular challenge because developing bodies are more sensitive to side effects of antipsychotics, particularly with respect to weight gain. In order to enroll a population that includes the younger ages, adolescents with other related psychiatric disorders are also included in this study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Adolescent
  • Otsuka,
  • Brexpiprazole
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects 13 to 17 years of age, inclusive, at the time of .
  • Subjects with a current diagnosis of primary schizophrenia spectrum or bipolar spectrum disorder, as defined by criteria, and confirmed by K-SADS-PL.
  • No psychiatric hospitalizations within the past 12 weeks.
  • Subjects require treatment with antipsychotic medications.
  • Subjects who have received previous outpatient antipsychotic treatment at an adequate dose for an adequate duration (at least 6 weeks) and who showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months.
  • Subjects with a body weight at Screening greater than or equal to 30 kg.

Exclusion criteria

Exclusion Criteria:

  • Sexually active females of and male subjects who are not practicing two different methods of with their partner (or abstinence) during the trial and for 30 days after the last dose of trial medication
  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving trial drug.
  • Subjects who have received continuous medication therapy to treat schizophrenia and schizophrenia spectrum diagnosis for less than six months prior to first dose of study medication AND subjects who have received continuous medication therapy to treat bipolar and bipolar spectrum disorder for less than two months in the past three years; or subjects who require more than one antipsychotic..
  • Subjects with a current diagnosis other than schizophrenia spectrum , bipolar spectrum, including any Axis I or Axis II (DSM-IV-TR) disorder.
  • Subjects with a clinical presentation and/or history of any neurodevelopmental disorder
  • Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days.
  • Subjects who currently have neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, seropositive status/acquired immunodeficiency syndrome, or chronic or C.
  • Subjects with IDDM (ie, any subjects using insulin) are excluded. Subjects with non-IDDM may be eligible for the trial if their condition is stable.
  • Subjects with epilepsy or a history of seizures.
  • Any major surgery or blood transfusion within 30 days prior to first dose of trial medication.
  • Subjects with a positive drug screen for cocaine or other illicit drugs, or alcohol are excluded and may not be retested or re-screened.
  • Prohibited concomitant medications used within the exclusionary period prior to Day 1 of the Dose Escalation Phase or anticipated need for such medications during the trial.
  • Subjects who participated in a clinical trial and were exposed to IMP within the last 30 days or who participated in more than two interventional clinical trials within the past year.
  • Subjects with a history of true allergic response (ie, not intolerance) to more than one class of medications.
  • Inability to tolerate oral medication or swallow tablets.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Cohort 1

    0.5 mg, Brexpipraxzole (OPC-34712)

    Drug: Brexpiprazole (OPC-34712)

  • Experimental
    Cohort 2

    1mg, Brexpipraxzole (OPC-34712)

    Drug: Brexpiprazole (OPC-34712)

  • Experimental
    Cohort 3

    2mg, Brexpipraxzole (OPC-34712)

    Drug: Brexpiprazole (OPC-34712)

  • Experimental
    Cohort 4

    3 mg, Brexpipraxzole (OPC-34712)

    Drug: Brexpiprazole (OPC-34712)

  • Experimental
    Cohort 5

    4mg, Brexpipraxzole (OPC-34712)

    Drug: Brexpiprazole (OPC-34712)

Interventions

  • Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.

06

What researchers measure

Primary outcomes

  1. Reported Adverse Events (AEs) at 30 day Follow-Up

    Time frame: 30 day Follow-Up

  2. Change from Baseline to Day 17 in Vital Signs

    Time frame: Baseline to Day 17

  3. Change from Baseline to Day 17 ECGs

    Time frame: Baseline to Day 17

  4. Change from Baseline to Day 17 Hematology

    Time frame: Baseline to Day 17

  5. Change from Baseline to Day 14 Physical examination

    Time frame: Baseline to Day 14

  6. Change from Baseline to Day 17 Body weight

    Time frame: Baseline to Day 17

  7. Change from Baseline to Day 17 Serum chemistry

    Including Prolactin concentrations

    Time frame: Baseline to Day 17

  8. Change from Baseline to Day 17 Urinalysis

    Time frame: Baseline to Day 17

  9. Maximal peak steady-state plasma concentration

    Time frame: At Day 14

  10. Minimum trough steady-state plasma concentration

    Time frame: At Day 14

  11. Time to maximum peak steady-state plasma concentration

    Time frame: At Day 14

  12. Area under the concentration-time curve during the dosing interval at steady-state

    Time frame: At Day 14

  13. Terminal elimination half-life

    Time frame: At Day 14

  14. For Brex only, apparent cleanse and apparent volume of distribution

    Time frame: At Day 14

Secondary outcomes

  1. Mean change in CGI-S score

    Time frame: Day -1 of Dose Titration Phase to Day 7 and Day 14 of Fixed Dose Phase

  2. Mean change in CGI-I score

    Time frame: Day 7 and Day 14

  3. Glycosylated haemoglobin [HbA1c]

    Time frame: Baseline to Day 17

  4. Change from Baseline to Day 17 Adrenocorticotropic hormone [ACTH]

    Time frame: Baseline to Day 17

  5. Change from Baseline to Day 17 Cortisol

    Time frame: Baseline to Day 17

  6. Change from Baseline to Day 17 Thyroid stimulating hormone [TSH]

    Time frame: Baseline to Day 17

  7. Change from Baseline to Day 17 Prothrombin time [PT]

    Time frame: Baseline to Day 17

  8. Change from Baseline to Day 17 Activated partial thromboplastin time [aPTT]

    Time frame: Baseline to Day 17

  9. Change from Baseline to Day 17 International normalized ratio [INR]

    Time frame: Baseline to Day 17

  10. For subjects with a current primary schizophrenia spectrum diagnosis, mean change in Positive and Negative Syndrom Scale (PANSS)

    Time frame: Day-1 to Day 15

  11. For subjects with a current diagnosis of bipolar spectrum disorder, mean change in Young Mania Rating Scale (YMRS)

    Time frame: Day -1 to Day 15

07

Study locations

10 sites
  • Little Rock, Arkansas 72211, United States
  • Culver City, California 90230, United States
  • Orange, California 92858, United States
  • Washington D.C., District of Columbia 20016, United States
  • Atlanta, Georgia 30331, United States
  • Marlton, New Jersey 08053, United States
  • Cincinnati, Ohio 45219, United States
  • Cleveland, Ohio 44106, United States
  • The Woodlands, Texas 77381, United States
  • Orem, Utah 84058, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2014
First posted
Apr 8, 2015
Start
Mar 2015
Primary completionActual
Jan 1, 2017
CompletionActual
Jan 1, 2017
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02411695
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
Mar 2015
Primary completion
Jan 1, 2017
Completion
Jan 1, 2017
Last update
Apr 28, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion